These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9303393)

  • 21. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2005 Nov; 43(11):5425-7. PubMed ID: 16272464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.
    Mikamo H; Sato Y; Tamaya T
    J Antimicrob Chemother; 2000 Sep; 46(3):485-7. PubMed ID: 10980180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species.
    Chryssanthou E; Cuenca-Estrella M
    J Clin Microbiol; 2002 Oct; 40(10):3841-4. PubMed ID: 12354895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).
    Bartizal K; Gill CJ; Abruzzo GK; Flattery AM; Kong L; Scott PM; Smith JG; Leighton CE; Bouffard A; Dropinski JF; Balkovec J
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2326-32. PubMed ID: 9371328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative evaluation of PASCO and national committee for clinical laboratory standards M27-A broth microdilution methods for antifungal drug susceptibility testing of yeasts.
    Arthington-Skaggs BA; Motley M; Warnock DW; Morrison CJ
    J Clin Microbiol; 2000 Jun; 38(6):2254-60. PubMed ID: 10834985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.
    Pfaller MA; Messer SA; Coffman S
    Antimicrob Agents Chemother; 1997 Apr; 41(4):763-6. PubMed ID: 9087485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests.
    Espinel-Ingroff A; Kerkering TM; Goldson PR; Shadomy S
    J Clin Microbiol; 1991 Jun; 29(6):1089-94. PubMed ID: 1864923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital.
    Arikan S; Sancak B; Hascelik G
    Med Mycol; 2005 Mar; 43(2):171-8. PubMed ID: 15832560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.
    Zhanel GG; Karlowsky JA; Harding GA; Balko TV; Zelenitsky SA; Friesen M; Kabani A; Turik M; Hoban DJ
    Antimicrob Agents Chemother; 1997 Apr; 41(4):863-5. PubMed ID: 9087508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of broth macrodilution, broth microdilution and E-test susceptibility tests of Cryptococcus neoformans for fluconazole.
    Chryssanthou E; Grönfors C; Khanna N
    Mycoses; 1997 Dec; 40(11-12):423-7. PubMed ID: 9470407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard.
    Barchiesi F; Colombo AL; McGough DA; Rinaldi MG
    J Clin Microbiol; 1994 Oct; 32(10):2494-500. PubMed ID: 7814488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique.
    Chen SC; O'Donnell ML; Gordon S; Gilbert GL
    J Antimicrob Chemother; 1996 Feb; 37(2):265-73. PubMed ID: 8707736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [In vitro activity of caspofungin against fluconazole-resistant Candida isolates from patients with HIV infection].
    Ortiz de la Tabla-Ducasse V; Masiá-Canuto M; Martín-González C; Gutiérrez-Rodero F
    Enferm Infecc Microbiol Clin; 2004; 22(6):328-31. PubMed ID: 15228899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
    Serrano Mdel C; Valverde-Conde A; Chávez M M; Bernal S; Claro RM; Pemán J; Ramirez M; Martín-Mazuelos E
    Diagn Microbiol Infect Dis; 2003 Feb; 45(2):131-5. PubMed ID: 12614985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida spp.
    Del Poeta M; Bixel AS; Barchiesi F; Tidwell RR; Boykin D; Scalise G; Perfect JR
    J Antimicrob Chemother; 1999 Aug; 44(2):223-8. PubMed ID: 10473229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.
    Peng T; Galgiani JN
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2126-31. PubMed ID: 8257134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions.
    Nelson PW; Lozano-Chiu M; Rex JH
    J Med Vet Mycol; 1997; 35(4):285-7. PubMed ID: 9292427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients.
    Chávez M; Bernal S; Valverde A; Gutierrez MJ; Quindós G; Mazuelos EM
    J Antimicrob Chemother; 1999 Nov; 44(5):697-700. PubMed ID: 10552989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.
    Pfaller MA; Messer SA; Boyken L; Hollis RJ; Rice C; Tendolkar S; Diekema DJ
    Diagn Microbiol Infect Dis; 2004 Mar; 48(3):201-5. PubMed ID: 15023430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.